A meta-analysis of 769 participants found a significantly greater in those treated with (GLP-1RAs) compared to placebo.
Weight loss (WL) was greater in the GLP-1RAs group with a standardized mean difference of 0.82.
In participants who started GLP-1RAs treatment within 6 months post-surgery, WL was also higher (standardized mean difference of 0.79).
Adverse events associated with GLP-1RAs were mostly gastrointestinal, particularly nausea, which occurred more often in the treatment group (odds ratio of 2.01).
Approximately 20-25% of patients experience (WR) after bariatric surgery, highlighting the need for effective management strategies.
Simplified
BACKGROUND: (WR) and insufficient (WL) occur in 20-25% of patients after bariatric surgery due to various factors. (GLP-1RAs) have shown promise in promoting WL; however, evidence regarding their effectiveness in managing WL and preventing WR post-bariatric surgery remains limited.
OBJECTIVE: This study aims to evaluate the role of GLP-1RAs in treating and preventing WR following bariatric surgery.
METHODS: A systematic search was conducted across PubMed, Scopus, and Web of Science for studies assessing the impact of GLP-1RAs on WR after bariatric surgery.
RESULTS: Our search identified 27 original studies, with 10 included in the meta-analysis involving 769 participants (392 treated with GLP-1RAs). The mean age was 44.05 years, with 30.47% male. The time interval from surgery to the initiation of GLP-1RAs treatment ranged from 1.5 to 86.7 months, with treatment durations between 4 and 12 months. The analysis showed significantly greater WL in the GLP-1RAs group compared to placebo (SMD = 0.82, 95% CI 0.23 to 1.42). Subgroup analysis for treatment durations ≤ 6 months indicated a higher WL in the GLP-1RAs group (SMD = 0.79, 95% CI 0.25 to 1.34). Adverse events were primarily gastrointestinal, with nausea significantly more frequently in the GLP-1RAs group (OR = 2.01, 95% CI 1.24 to 3.27).
CONCLUSION: GLP-1RAs effectively promote WL among participants experiencing WR after bariatric surgery. Initiating GLP-1RAs therapy shortly after surgery may help prevent WR. Further research is warranted to explore long-term outcomes and optimize treatment protocols for this patient population.
Key numbers
0.82
Increase in
Standardized mean difference (SMD) for GLP-1RAs vs. placebo.
2.01
Higher Incidence of Nausea
Odds ratio (OR) for nausea in GLP-1RAs group vs. placebo.
0.79
in Short-Term Treatment
Standardized mean difference (SMD) for treatment durations ≤ 6 months.
Full Text
We can’t show the full text here under this license.
